QE II Health Sciences Center

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
3	Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)	Terminated	Closed	Nilotinib or Imatinib	NCT00751036